Aytu Biopharma, Inc (AYTU): Revenue
$57.57M
Year ended 2026-06-30
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $57.57M | -13.3% | 2026-09-22, From 2025-07-01 |
| 2025-06-30 | $66.38M | +1.8% | 2026-09-22, From 2024-07-01 |
| 2024-06-30 | $65.18M | n/c | 2025-09-23, From 2023-07-01 |
| 2023-06-30 | $107.40M | +11.1% | 2024-09-26, From 2022-07-01 |
| 2022-06-30 | $96.67M | +47.3% | 2023-10-12, From 2021-07-01 |
| 2021-06-30 | $65.63M | +137.5% | 2022-09-27, From 2020-07-01 |
| 2020-06-30 | $27.63M | +277.5% | 2021-09-28, From 2019-07-01 |
| 2019-06-30 | $7.32M | +100.0% | 2020-10-06, From 2018-07-01 |
| 2018-06-30 | $3.66M | +13.6% | 2019-09-26, From 2017-07-01 |
| 2017-06-30 | $3.22M | +25.7% | 2018-09-06, From 2016-07-01 |
| 2016-06-30 | $2.56M | +878.8% | 2017-08-31, From 2015-07-01 |
| 2015-06-30 | $261.8K | +344.2% | 2016-09-01, From 2014-07-01 |
| 2014-06-30 | $58.9K | n/a | 2015-09-28, From 2013-07-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $57.57M | -13.3% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $55.23M | -43.9% |
| Journey Medical Corp (DERM) | 2025-12-31 | $61.24M | +11.1% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $54.03M | +48.0% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $53.74M | n/a |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $62.38M | +48.3% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $62.90M | +699.0% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $63.26M | +9.7% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $51.95M | -18.5% |
Compare AYTU, NKTR, DERM, AGIO side by side · Screen every company in Pharmaceutical Preparations ↗